Cargando…

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer

Understanding the molecular mechanisms underlying prostate cancer (PCa) progression towards its most aggressive, castration-resistant (CRPC) stage is urgently needed to improve the therapeutic options for this almost incurable pathology. Interestingly, CRPC is known to be characterized by a peculiar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontana, Fabrizio, Limonta, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151003/ https://www.ncbi.nlm.nih.gov/pubmed/34067217 http://dx.doi.org/10.3390/cells10051133

Ejemplares similares

The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012)

Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
por: Fontana, Fabrizio, et al.
Publicado: (2020)

Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer
por: Fontana, Fabrizio, et al.
Publicado: (2023)

AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638
por: Zhou, Wen, et al.
Publicado: (2014)

Targeting the adaptive molecular landscape of castration-resistant prostate cancer
por: Wyatt, Alexander W, et al.
Publicado: (2015)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Adipocytes reprogram prostate cancer stem cell machinery
por: Fontana, Fabrizio, et al.
Publicado: (2023)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
por: Grasso, Catherine S., et al.
Publicado: (2012)

Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
por: Fontana, Fabrizio, et al.
Publicado: (2020)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery
por: Fontana, Fabrizio, et al.
Publicado: (2020)

Exploiting the Metabolic Consequences of PTEN Loss and Akt/Hexokinase 2 Hyperactivation in Prostate Cancer: A New Role for δ-Tocotrienol
por: Fontana, Fabrizio, et al.
Publicado: (2022)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

A Changing Landscape in Castration-Resistant Prostate Cancer Treatment
por: Felici, A., et al.
Publicado: (2012)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression
por: Fontana, Fabrizio, et al.
Publicado: (2022)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
por: Turco, Fabio, et al.
Publicado: (2022)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
por: Meagher, Margaret F, et al.
Publicado: (2023)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Cancer Stem Cells—Key Players in Tumor Relapse
por: Marzagalli, Monica, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
por: Inoue, Takahiro, et al.
Publicado: (2011)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Adipocyte-Derived Extracellular Vesicles Promote Prostate Cancer Cell Aggressiveness by Enabling Multiple Phenotypic and Metabolic Changes
por: Fontana, Fabrizio, et al.
Publicado: (2022)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
por: Parker, Daniel C., et al.
Publicado: (2020)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
por: Leung, David Ka-Wai, et al.
Publicado: (2021)

Castration-resistant prostate cancer: systemic therapy in 2012
por: Maluf, Fernando C., et al.
Publicado: (2012)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rdttnmmsvsq9ps09lp3d634md4